A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

Inclusion Criteria:

• Male or female, aged 18-80 years (both inclusive) at the time of signing theinformed consent

• Body mass index (BMI) between 20.0 and 39.9 kilogram per square meter (kg/m^2) (bothinclusive) at screening.

• Meeting the pre-defined eGFR values based on the Chronic Kidney Disease EpidemiologyCollaboration (CKD-EPI) creatinine equation (2021) adjusted for the estimatedindividual body surface area (BSA);

• Normal renal function - greater than or equal to 90 mL/min

• Mild renal impairment - 60 - 89 (mL/min)

• Moderate renal impairment - 30 - 59 (mL/min)

• Severe renal impairment - less than 30 (mL/min) not requiring dialysis

• End-stage renal disease (ESRD) - Requiring dialysis treatment

• For ESRD: Participants requiring dialysis treatment should be on current treatmentwith haemodialysis.

Exclusion Criteria:

• Any disorder, unwillingness, or inability which in the investigator's opinion mightjeopardize participant's safety or compliance with the protocol.

• Use of drugs known to affect creatinine clearance including cephalosporin andaminoglycoside, antibiotics, flucytosine, cisplatin, cimetidine, trimethoprim,cibenzoline, and nitrofurantoin within 14 days or 5 half-lives, whichever isgreater, before dosing the investigational medicinal product (IMP).

• Presence or history of any clinically relevant respiratory, metabolic, hepatic,cardiovascular, gastrointestinal, or endocrinological conditions(except conditionsassociated with renal impairment or ESRD).